Background
Omalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin E (IgE). IgE promotes the release of inflammatory mediators from mast cells and basophils during allergic and inflammatory reactions. By binding to IgE and neutralizing it, omalizumab reduces free IgE levels and prevents IgE from binding to its receptors on immune cells. It is used to treat a range of immune and inflammatory conditions, including allergies, urticaria, and asthma.
Product Details
| Reactivity | Human |
| Specificity | Detects human IgE in direct ELISA. This non-therapeutic antibody uses the same variable region sequences (VH, VL) as the therapeutic antibody Omalizumab. This product is for research use only. |
| Source | Recombinant Monoclonal Human IgG1 Clone #FB006 |
| Purification | Protein A/G purified from CHO cell culture supernatant |
| Immunogen | Human IgE |
| Endotoxin Level | <0.10 EU per 1 µg of the antibody by the LAL method |
| Formulation | 0.2 µm filtered solution in PBS |
| Applications | • ELISA: This antibody functions as an ELISA detection antibody for the specific antigen in direct ELISA. Colorimetric detection is performed after addition of a suitable substrate. |
| Reconstitution | Reconstitute at 0.5 mg/ml in sterile 1xPBS |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at -20 to -70°C |
| Storage Conditions | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. • 12 months from the date of receipt at -20 to -70°C as supplied. • 1 month at 2 to 8°C under sterile conditions |